Palisade Bio (NASDAQ:PALI) reported quarterly losses of $(0.12) per share. This is a 97.07 percent increase over losses of $(4.10) per share from the same period last year.
Organovo Advances Clinical Timelines For FXR314 And Provides Updates On NASH Phase 2 Data
Organovo Holdings, Inc.